Article
MUC3A induces PD-L1 and reduces tyrosine kinase inhibitors effects in EGFR-mutant non-small cell lung cancer.
International journal of biological sciences - 1 Jan 2021
Luo Yuan, Ma Shijing, Sun Yingming, Peng Shan, Zeng Zihang, Han Linzhi, Li Shuying, Sun Wenjie, Xu Jieyu, Tian Xiaoli, Wang Feng, Wu Qiuji, Xiao Yu, Zhang Junhong, Gong Yan, Xie Conghua
Abstract excerpt
The immune checkpoint ligand programmed death-ligand 1 (PD-L1) and the transmembrane mucin (MUC) 3A are upregulated in non-small cell lung cancer (NSCLC), contributing to the aggressive pathogenesis and poor prognosis. Here, we report that knocking down the oncogenic MUC3A suppresses the PD-L1 expression in NSCLC cells. MUC3A is a potent regulator of epidermal growth factor receptor (EGFR) stability, and MUC3A...
Topics
Join the communities discussing this publication.